Introduction: Lymphoproliferative disorders, including lymphomas and leukemias, pose a major public health concern due to their considerable morbidity and mortality. In Brazil, data from the National Cancer Institute (INCA) estimate over 10,000 new cases of non-Hodgkin lymphoma and more than 6,000 of leukemia annually, with high mortality especially among older adults. Understanding the epidemiological distribution of these diseases by sex and age is key to informing prevention strategies and promoting early diagnosis. Objective:To analyze epidemiological trends of lymphoproliferative malignancies in an oncology hospital in Belém, Pará, with emphasis on prevalence by histological type. Methods: This analytical study used data from the Population-Based Cancer Registry (RCBP) of Belém, collected by INCA from 2015 to 2019. A total of 1,186 cases were included and classified by histological type according to ICD-O-3 codes. Data were presented in absolute numbers and percentages. Results: Among the total cases, 52.8% (n = 626) occurred in males and 47.2% (n = 560) in females. The most frequent histological types in men were myeloid leukemia (20.61%), lymphoid leukemia (20.45%), and diffuse malignant lymphoma/not otherwise specified (NOS) (19.49%). Among women, the predominant types were malignant lymphoma NOS (19.64%), plasma cell tumors (14.46%), and myeloid leukemia (18.39%). In terms of age, 46.3% of all patients were aged 60 years or older, followed by 32.5% between 40 and 59 years. The age group 0–19 years accounted for only 7.9% of cases, highlighting the predominance of these diseases in adult and elderly populations. Conclusion: The findings indicate important sex- and age-related differences in the profile of lymphoproliferative diseases. Leukemias and B-cell lymphomas were more prevalent in men, while plasma cell tumors were more common in women. Most cases occurred in older individuals, emphasizing the role of aging as a risk factor. Furthermore, a significant portion of the patients resided in socioeconomically disadvantaged urban areas, suggesting that social determinants may influence both access to care and disease outcomes. These results support the need for targeted early detection programs and regional policies that address both biomedical and social determinants of cancer.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
